Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Tolerability Study With Single Ascending Doses of ORM-12741

This study has been completed.
Information provided by:
Orion Corporation, Orion Pharma Identifier:
First received: May 30, 2008
Last updated: February 10, 2010
Last verified: February 2010
The purpose of this study is to evaluate the safety and tolerability of escalating doses of ORM-12741 in healthy volunteers.

Condition Intervention Phase
Drug: ORM-12741
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Single Ascending Doses of ORM-12741

Further study details as provided by Orion Corporation, Orion Pharma:

Primary Outcome Measures:
  • Safety measures, i.e. assessing adverse events, vital signs, ECG, safety laboratory values [ Time Frame: About 8 weeks ]

Secondary Outcome Measures:
  • Pharmacokinetics [ Time Frame: 5 days after each dose ]

Enrollment: 120
Study Start Date: July 2008
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ORM-12741 Drug: ORM-12741
Alternating panel single dose escalation.
Placebo Comparator: Placebo Drug: ORM-12741
Alternating panel single dose escalation.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Good general health ascertained by detailed medical history and physical examinations
  • Males between 18 and 45 years
  • Body mass index (BMI) between 18-30 kg/m2
  • Weight 55-90 kg

Exclusion Criteria:

  • Evidence of clinically significant cardiovascular, renal, hepatic, haematological, gastro-intestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric disease
  • Any condition requiring regular concomitant treatment including herbal products or likely to need any concomitant treatment during the study
  • Susceptibility to severe allergic reactions
  • Regular consumption of more than 14 units of alcohol per week
  • Current use of nicotine-containing products more than 5 cigarettes or equivalent/day
  • Inability to refrain from using nicotine-containing products during the stay in the study centre
  • Inability to refrain from consuming caffeine-containing beverages during the stay in the study centre
  • Blood donation or loss of significant amount of blood within 3 months prior to the screening visit
  • Abnormal finding in ECG, vital signs, laboratory tests or physical examination
  • Participation in a drug study within 3 months prior to the start of this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00693316

Forenap Pharma
Rouffach, France, 68250
Sponsors and Collaborators
Orion Corporation, Orion Pharma
Principal Investigator: Déborah Metzger, MD Forenap Pharma
  More Information

Responsible Party: Jutta Hänninen, Clinical study manager, Orion corporation, Orion Pharma Identifier: NCT00693316     History of Changes
Other Study ID Numbers: 3098001
Study First Received: May 30, 2008
Last Updated: February 10, 2010

Keywords provided by Orion Corporation, Orion Pharma:
Healthy volunteer study processed this record on May 25, 2017